Presidio Property Trust Inc. (SQFT)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Presidio Property Trust, Inc. Announces Earnings for the Second Quarter Ended June 30, 2024
SAN DIEGO, CA / ACCESSWIRE / August 14, 2024 / Presidio Property Trust, Inc. (NASDAQ:SQFT)(NASDAQ:SQFTP)(NASDAQ:SQFTW) (the "Company"), an internally managed, diversified real estate investment trust ("REIT"), today reported earnings for its quarter ended June 30, 2024. "During the first and second quarters, we entered into 10 leases with new tenants totaling nearly 36,000 sf.
Presidio Property Trust Announces Pricing of $1.74 Million Public Offering of Series D Preferred Stock
SAN DIEGO, CA / ACCESSWIRE / June 20, 2024 / (NASDAQ:SQFT) Presidio Property Trust, an internally managed, diversified real estate investment trust ("REIT"), today announced the pricing of its public offering of 109,054 shares of its 9.375% Series D Cumulative Redeemable Perpetual Preferred Stock par value $0.01 per share (the "Series D Preferred Stock") at a price to the public of $16.00 per share. Gross proceeds from the offering are expected to be approximately $1.74 million, before deducting underwriting discounts and offering expenses.
Presidio Property Trust Inc. (SQFT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Presidio Property Trust Inc. ever had a stock split?
Presidio Property Trust Inc. Profile
| Diversified REITs Industry | Real Estate Sector | Jack Kendrick Heilbron CEO | NASDAQ (CM) Exchange | 74102L501 CUSIP |
| US Country | 15 Employees | 15 Dec 2023 Last Dividend | 19 May 2025 Last Split | 7 Oct 2020 IPO Date |
Overview
Presidio is a versatile and diversified Real Estate Investment Trust (REIT) with a strategic focus on model home properties, office spaces, industrial sites, and retail locations. By leveraging an internal management approach, Presidio has successfully constructed a robust portfolio with a geographical concentration in key states including Arizona, Illinois, Texas, Wisconsin, Florida, Colorado, Maryland, North Dakota, and Southern California. Despite the significant operational advantages garnered through geographical clustering, such as reduced operating costs via economies of scale, Presidio remains vigilant of the vulnerabilities inherent to localized market fluctuations, which have been further emphasized by the COVID-19 pandemic. Diversifying its investment strategy beyond real estate, Presidio holds approximately 6.5% of the outstanding common stock in Conduit Pharmaceuticals Inc., a pioneering life science entity engaged in the development of treatments across various diseases, thus highlighting Presidio's multifaceted investment framework.
Products and Services
- Model Home Properties
- Office Properties
- Industrial Properties
- Retail Properties
- Investment in Conduit Pharmaceuticals Inc.
Presidio capitalizes on the lucrative model home leasing sector, providing triple-net lease agreements to prominent homebuilders. These properties are strategically located across Arizona, Illinois, Texas, Wisconsin, and Florida, offering a reliable and steady income stream by catering to the housing industry's showcase needs.
The company's portfolio includes office properties primarily situated in Colorado, with additional locations in Maryland, North Dakota, Texas, and Southern California. These spaces cater to a broad range of businesses seeking strategically located and well-managed office environments.
Presidio's industrial offerings accommodate a diverse spectrum of operational needs, from storage to manufacturing. The geographic diversity of these properties ensures resilience and flexibility in serving the dynamic requirements of industrial tenants.
Retail locations, forming an integral part of Presidio's real estate portfolio, are primarily located in Colorado. These properties support a wide array of retailers by providing strategically positioned, consumer-accessible spaces that drive foot traffic and sales.
Expanding beyond real estate, Presidio has invested in Conduit Pharmaceuticals Inc., acquiring a stake in its innovative approach to pharmaceutical development. This investment reflects Presidio's commitment to diversification and its belief in the potential of Conduit's disease-agnostic model for compound development.
